Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Current Fiscal Year End Date Entity Small Business Entity Shell Company Entity Emerging Growth Company Entity Current Reporting Status Document Period End Date Entity Filer Category Document Fiscal Period Focus Document Fiscal Year Focus Entity Common Stock Shares Outstanding Document Quarterly Report Document Transition Report Entity Interactive Data Current Entity File Number Entity Tax Identification Number Entity Address Postal Zip Code Entity Incorporation State Country Code Entity Address Address Line 1 Entity Address City Or Town Entity Address State Or Province Local Phone Number City Area Code Trading Symbol Security Exchange Name Security 12b Title CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) ASSETS Current assets: Cash and cash equivalents Accounts receivable, net Inventories Prepaid expenses and other current assets Total current assets [Assets, Current] Property and equipment, net Intangible assets, net Goodwill Deposits and other assets TOTAL ASSETS [Net Assets] LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable Accrued expenses and other current liabilities Current portion of deferred revenue Current portion of lease obligations Total current liabilities [Liabilities, Current] Senior notes payable, net of discount Deferred revenue, net of current portion Subordinated note payable, net of discount Lease obligations, net of current portion Other non-current liabilities TOTAL LIABILITIES [Liabilities] COMMITMENTS AND CONTINGENCIES STOCKHOLDERS' EQUITY Stockholders' Equity Attributable to Parent [Abstract] Preferred Stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued and outstanding Common Stock, $0.0001 par value, 150,000,000 shares authorized, 86,349,981 and 59,318,355 shares issued and outstanding Additional paid-in capital Accumulated deficit TOTAL STOCKHOLDERS' EQUITY [Stockholders' Equity Attributable to Parent] TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY [Liabilities and Equity] STOCKHOLDERS' EQUITY Preferred stock, shares par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, shares par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) REVENUES: Product revenue License revenue Total Revenues [Revenues] OPERATING EXPENSES: Cost of product revenue (exclusive of amortization expense shown below) Research and development Plasma center operating expenses Amortization of intangible assets Selling, general and administrative Total operating expenses [Operating Expenses] LOSS FROM OPERATIONS [Operating Income (Loss)] OTHER INCOME (EXPENSE): Interest and other income Interest expense [Interest Expense] Loss on extinguishment of debt [Gain (Loss) on Extinguishment of Debt] Gain on transfer of plasma center assets Other expense, net Other expense, net [Nonoperating Income (Expense)] NET LOSS [Net Income (Loss) Attributable to Parent] BASIC AND DILUTED LOSS PER COMMON SHARE WEIGHTED AVERAGE COMMON SHARES OUTSTANDING: Basic and Diluted CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (Unaudited) Statement [Table] Statement [Line Items] Statement Equity Components [Axis] Common Stock Additional Paid-In Capital Accumulated Deficit Balance, shares [Shares, Issued] Balance, amount Stock-based compensation Issuance of common stock, net of offering expenses, shares Warrants issued in connection with note payable Issuance of common stock, net of offering expenses, amount Net loss Exercise of stock options, shares Exercise of stock options, amount Balance, shares Balance, amount CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) CASH FLOWS FROM OPERATING ACTIVITIES: Net loss Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization Loss on disposal of fixed assets Stock-based compensation [Share-based Payment Arrangement, Noncash Expense] Gain on transfer of plasma center assets Amortization of debt discount Loss on extinguishment of debt Amortization of license revenue Changes in operating assets and liabilities, net of acquisition: Accounts receivable Inventories [Increase (Decrease) in Inventories] Prepaid expenses and other current assets [Increase (Decrease) in Prepaid Expense] Deposits and other assets [Increase (Decrease) in Other Operating Assets] Accounts payable [Increase (Decrease) in Accounts Payable] Accrued expenses Other current and non-current liabilities Net cash used in operating activities [Net Cash Provided by (Used in) Operating Activities] CASH FLOWS FROM INVESTING ACTIVITIES: Purchase of property and equipment Proceeds from the sale of property and equipment Net cash used in investing activities CASH FLOWS FROM FINANCING ACTIVITIES: Principal payments on notes payable Payment of end of term fee [Payments for Other Fees] Payment of debt refinancing fees [Payment of debt refinancing fees] Proceeds from issuance of note payable Payment of debt issuance costs [Payments of Debt Issuance Costs] Proceeds from the issuance of common stock, net of offering expenses Proceeds from the exercise of stock options Payments on finance lease obligations [Payments for Leasing Costs] Net cash provided by financing activities [Net Cash Provided by (Used in) Financing Activities] Net increase in cash and cash equivalents [Cash and Cash Equivalents, Period Increase (Decrease)] Cash and cash equivalents, including restricted cash - beginning of period Cash and cash equivalents - end of period ORGANIZATION AND BUSINESS 1. ORGANIZATION AND BUSINESS SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES INVENTORIES 3. INVENTORIES INTANGIBLE ASSETS 4. INTANGIBLE ASSETS PROPERTY AND EQUIPMENT 5. PROPERTY AND EQUIPMENT DEBT 6. DEBT STOCKHOLDERS' EQUITY 7. STOCKHOLDERS' EQUITY RELATED PARTY TRANSACTIONS 8. RELATED PARTY TRANSACTIONS COMMITMENT AND CONTINGENCIES 9. COMMITMENTS AND CONTINGENCIES SEGMENTS 10. SEGMENTS TRANSFER OF PLASMA CENTER ASSETS 11. TRANSFER OF PLASMA CENTER ASSETS LEASE OBLIGATIONS 12. LEASE OBLIGATIONS SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION 13. SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION SUBSEQUENT EVENTS 14. SUBSEQUENT EVENTS Basis of presentation Use of estimates Fair value of financial instruments Accounts receivable Receivable [Policy Text Block] Inventories Inventory, Policy [Policy Text Block] Goodwill Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] Impairment of long-lived assets Revenue recognition Cost of product revenue Loss per common share Stock-based compensation Compensation Related Costs, Policy [Policy Text Block] Income Taxes Recent Accounting Pronouncements Schedule of dilutive securities Schedule of inventory Intangible asset future aggregate amortization expense Schedule of Intangible assets Schedule of property and equipment Summary of subordinated note payable Summary of notes payable Schedule of assumptions Schedule of compensation expense Schedule of option activity Schedule of stock-based compensation expense Summarized segment financial information Schedule of future minimum lease payments Schedule of supplemental cash flow information Cash and cash equivalents Working capital Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities Axis Stock Options [Member] Restricted stock units [Member] Warrants [Member] Potentially dilutive securities Award Date [Axis] Related Party Transaction [Axis] Concentration Risk Type [Axis] Concentration Risk Benchmark [Axis] January 1, 2019 [Member] Biotest [Member] Customer Three [Member] Accounts Receivable [Member] Customer Two [Member] Goodwill Vesting term Right of use assets Lease liability Note payable Risk concentration Raw materials Work-in-process Finished goods Total inventories Finite Lived Intangible Assets By Major Class Axis Trademark and other intangible rights related to Nabi-HB [Member] Right to intermediates [Member] Customer contract [Member] Cost Accumulated amortization Net Remainder of 2020 2021 2022 2023 2024 Amortization expense Property Plant And Equipment By Type Axis Manufacturing and laboratory equipment [Member] Office equipment and computer software [Member] Furniture and fixtures [member] Leasehold improvements [Member] Land [Member] Buildings [Member] Construction in process [Member] Property, plant and equipment, gross Less: accumulated depreciation and amortization [Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment] Property, plant and equipment, net Range [Axis] Property and equipment [Member] Maximum [Member] Depreciation expense Useful life Notes payable Less: Debt discount Senior notes payable Subordinated note payable to Biotest Less: Debt discount [Debt discount] Subordinated note payable Plan Name [Axis] Title of Individual [Axis] Short-term Debt, Type [Axis] Perceptive Credit Agreement [Member] BPC (Member) Perceptive Tranche III Warrant [Member] Marathon Healthcare Finance Fund, L.P. (Member) Perceptive Tranche III Loan (Member) Perceptive Tranche II Loan (Member) Perceptive Tranche I Loan (Member) Perceptive Tranche I Note and Perceptive Tranche II fees paid Interest rate Description of prepaid principal amount Principal amount of term loan Additionlal description Interest rate description Warrant Warrant, amount Expiration date Warrant exercise price Net Cash proceeds Deferred facility fee Loss on the extinguishment of debt Prepayment Penalty Unamortized debt discount Fees and expenses Additional facility fee Debt service reserve Accrued interest Maximum [Member] Minimum [Member] Dividend yield Expected term Volatility Risk-free interest rate Shares Outstanding at beginning of period [Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number] Forfeited Expired Granted Exercised Outstanding at end of period Options exercisable Weighted Average Exercise Price Outstanding at beginning of period [Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price] Forfeited [Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price] Expired [Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price] Granted Exercised [Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price] Outstanding at end of period Options exercisable [Options exercisable] Shares Granted Vested Forfeited Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Granted Vested [Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value] Forfeited Income Statement Location Axis Research and development [Member] Plasma centers [Member] Selling, general and administrative [Member] Cost of product revenue [Member] Stock-based compensation Equity Incentive Plans [Member] Preferred stock, par value Preferred stock, shares authorized Preferred stock, outstanding Common stock, par value Common stock, shares authorized Underwritten public offering Common stock shares, issued Gross proceeds from public offering Common stock, outstanding Common stock reserved for outstanding Common stock issuable Warrants outstanding Weighted average exercise price of warrants Unrecognized compensation expense recognition period Options granted Weighted average remaining contractual life of stock options exercisable Weighted average remaining contractual life of stock options outstanding Unrecognized compensation expense Compensation expense Common stock granted Related Party [Axis] Areth, LLC [Member] Credit facility Public offering description Rent expense Monthly Rent Debt instrument, frequency of periodic payment Purchase percentage from inventory Purchase of raw material Plasma supply agreement term Segments [Axis] Consolidated (member) Plasma Collection Centers Corporate ADMA BioManufacturing Revenues Cost of product revenue Loss from operations Interest and other expense, net Gain on transfer of plasma center assets Capital expenditure Depreciation and amortization expense TOTAL ASSETS [TOTAL ASSETS] Gain upon transfer facilities Net carrying value of assets Combined fair value of obligation Remainder of 2020 [Operating Leases, Future Minimum Payments, Remainder of Fiscal Year] 2021 [Operating Leases, Future Minimum Payments, Due in Two Years] 2022 [Operating Leases, Future Minimum Payments, Due in Three Years] 2023 [Operating Leases, Future Minimum Payments, Due in Four Years] 2024 [Operating Leases, Future Minimum Payments, Due in Five Years] Thereafter Total payments Less: imputed interest [Less: imputed interest] Current portion [Operating Lease, Liability, Current] Total [Total] Lease and rent expense Lease description Operating Lease liabilities Weighted average remaining term Right of use asstes Incremental borrowing rate SUPPLEMENTAL INFORMATION: Cash paid for interest Noncash Financing and Inesting Activities: Equipment acquired reflected in accounts payable and accrued liabilities Right-to-use assets obtained in exchange for lease obligations Warrants issued in connection with note payable [Warrants issued in connection with note payable] Subsequent Event Type [Axis] Consolidated Entities [Axis] Subsequent Event [Member] Sale Agreement [Member] Jefferies LLC [Member] Common stock, par value Common stock offering Commission description